HIV/AIDS
Co-administration of lopinavir decreases amprenavir concentration
Published in AIDS Weekly, June 28th, 2004
According to recent research from Germany, "In a controlled, prospective study, the efficacy of ritonavir 200 mg twice daily (bid) in inhibiting the decrease of amprenavir plasma concentrations caused by co-administration of lopinavir was assessed. Twelve HIV-seropositive patients were enrolled, and nine patients completed the 28-day study."
"At day 14," reported S. Mauss and coworkers, "plasma concentrations of amprenavir 600 mg bid and ritonavir 200 mg bid were determined over 12 hours. At day 15, lopinavir 400 mg bid was added. At day 28, plasma...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2004-06-28)
More Articles from AIDS Weekly
- HIV & Cancer
EBV may play role in pathogenesis of head and neck cancers in HIV infection - HIV/AIDS Research
Dendrites cross-present HIV antigens from live and apoptotic infected CD4+ cells - HIV/AIDS Research
Unusual ''senseless'' 2',5'-oligoribonucleotide has potent anti-HIV activity - HIV/AIDS Treatment
Drug interactions occur between opioids and antiretroviral medications - Antifungal Agents
New antifungal agents offer prospects for treatment - Awards
HIV/AIDS media campaign receives Peabody/Robert Wood Johnson Foundation Award - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
